Item 2.02. Results of Operations and Financial Condition.

On August 4, 2022, Akebia Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2022 and commenting on certain business updates. A copy of the Company's press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On August 4, 2022, the Company issued the press release furnished as Exhibit 99.2 to this Report and incorporated herein by reference.

The information in this Report (including Item 2.02, Item 7.01, Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits

Exhibit No.                                  Description

99.1                Press Release, dated August 4, 2022, issued by Akebia
                  Therapeutics, Inc.

99.2                Press Release, dated August 4, 2022, issued by Akebia
                  Therapeutics, Inc.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses